microtubule inhibitor-185322

Microtubule inhibitor 185322 is an inhibitor of microtubule assembly, inducung mitotic arrest and apoptosis of MM cells.

Compounds 17o (IC50: 14.0 nM, NCI-H460) and 17p (IC50: 2.9 nM, NCI-H460) with furan moieties showed potent cytotoxic effects at the nanomolar level against various human cancer cell lines.

Microtubule inhibitor 2 is a highly potent and selective microtubule inhibitor, which is orally active. It induces cell death via ferroptosis, and exhibits notable antitumor activity [1].

Microtubule inhibitor 4 (compound 2) is a potent microtubule inhibitor that prevents microtubule protein polymerization and exhibits cytotoxicity in HT-29 cells (IC50: 2.1 nM).

Microtubule inhibitor 6 (compound 17o) is a potent microtubule inhibitor exhibiting cytotoxicity against NCI-H460, BxPC-3, and HT-29 cells, with IC50 values of 14.0, 6.6, and 7.0 nM, respectively. It effectively inhibits microtubule polymerization.

Compounds 17o (IC50= 14.0 nM, NCI-H460) and 17p (IC50= 2.9 nM, NCI-H460) with furan moieties show potent nanomolar levels of cytotoxic activity against various human cancer cell lines.

Microtubule inhibitor 1 is an antitumor agent that inhibits microtubule polymerization with an IC50 of 9-16 nM in cancer cells.

Microtubule inhibitor 5 (compound 17f) is a highly potent cytotoxic agent that inhibits microtubule function, exhibiting a substantial cytotoxic effect on NCI-H460 cells with an IC50 value of 154.5 nM. Additionally, this compound demonstrates excellent cell permeability [1].

Microtubule Inhibitor 8 (MP-HJ-1b) serves as a potent disruptor of microtubule function, inducing cell death via ferroptosis and demonstrating anti-tumor effects [1] [2].

Niguldipine Free Base is a calcium channel blocker and a₁-adrenergic receptor antagonist and a clinical modulator of multidrug resistance.